The National Health Service in England (NHS England) does not provide pre-exposure prophylaxis (PrEP) against HIV, forcing people to purchase generic versions on the internet. However, there are concerns about the authenticity of medicines purchased online. We established an innovative service offering plasma tenofovir (TFV) and emcitrabine (FTC) therapeutic drug monitoring for people buying generic PrEP online, to ensure that drug concentrations in vivo were consistent with those of propriety brands and previously published data.
Introduction
Several studies have shown that the combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) dramatically reduces the risk of HIV acquisition when taken daily or in an event-driven manner by people who are HIV negative [1] [2] [3] . As a result, the World Health Organization (WHO) Guidelines on Use of Antiretrovirals for HIV Treatment and Prevention updated in 2015 recommended HIV pre-exposure prophylaxis (PrEP) as an additional prevention strategy for key populations and extended its use to anyone at risk [4] . Consequently, several countries in Africa, Asia, Europe and Latin America have introduced oral PrEP with TDF/FTC into national HIV prevention guidelines. However, many health services, including the National Health Service (NHS) in England, have declined to fund PrEP because of its high cost and the potential adverse impact this would have on expenditure [5] . There was a recent announcement that a clinical trial would be started to treat 10 000 people in the UK with PrEP over the next 3 years. However, no details of how this trial will operate have emerged, and it is unclear how the TDF/FTC will be obtained for the £10 million allocated budget [6] .
Up to the end of 2016, lack of availability of PrEP on the NHS has forced at-risk individuals to purchase generic versions on the internet (e.g. via websites such as www.iwant prepnow.co.uk), which is legal under UK import laws [7] . This is possible because branded antiretroviral agents are becoming available globally as generic drugs at low cost and has occurred because of voluntary licensing rules. This is the case for TDF/FTC, a combination that is restricted by patent until 2021 [8] .
Although generic manufacturing companies produce preparations of TDF/FTC that are bioequivalent to the branded product and Food and Drug Administration (FDA)-approved drugs [9] , there are concerns about the authenticity of medicines purchased online. Fake versions of drugs have come onto the market in the past. Viagra, for example, was found to be produced in unsanitary conditions in garages, basements, and warehouses, where the drug calibrations are likely to have been incorrect. Batches reported to authorities were discovered to contain only traces of the active ingredient sildenafil citrate, and contaminated with other substances including talcum powder, commercial paint and printer ink [10] .
Rates of HIV acquisition in men who have sex with men (MSM) and other groups in the UK remain high [11] and PrEP is a crucial strategy to reduce this risk.
There is extensive demand for PrEP in London, with sexual health clinics reporting increasing numbers of people who have purchased TDF/FTC on the internet and who seek advice. Many of these individuals have no access to safety monitoring and are concerned about the authenticity of the product they have purchased.
In response to this, in February 2016, we established an innovative service offering plasma tenofovir (TFV) and FTC therapeutic drug monitoring (TDM) for people buying generic PrEP online, to ensure that drug concentrations were consistent with previously published data. In this article, we describe our service.
Methods
All HIV-negative individuals attending 56 Dean Street (from February to October 2016) who reported purchasing PrEP on the internet were offered TDM in addition to tests for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and renal function. There were no other inclusion/exclusion criteria. This analysis was approved by Chelsea and Westminster Hospital NHS Foundation Trust, the database used was registered by the HIV/Genito-urinary Medicine Directorate and all data were recorded anonymously.
Whole blood was collected in ethylenediaminetetraacetic acid (EDTA) blood tubes and information on the timing of the last TDF/FTC dose and of blood collection was recorded on a laboratory request form.
Following blood collection, each sample was centrifuged for 10 min at 2000 g at 4°C. Plasma was then aliquotted equally into two 2.0-mL tubes (Sarstedt, N€ umbrecht, Germany) and stored at À80°C. Samples were prepared and analysed for drug concentrations by Jefferiss Trust Laboratories, London, UK. Briefly, 200 lL of plasma was combined with 200 lL of 4% phosphoric acid and 10 lL of working internal standard solution (50 lg/mL of lidocaine). The sample was subject to solid-phase extraction (Oasis MCX 1 cc Vac Cartridge (Waters Chromatography B.V., EttenLeur, The Netherlands); 30 mg of sorbent; 30 lm particle size) before analysis. The MCX cartridge was conditioned with 2 mL of methanol, followed by 2 mL of water. After loading the sample mixture, the MCX cartridge was washed with 1 mL of 2% formic acid followed by 1 mL of methanol. The sample was eluted with 1 mL of 10% ammonia in acetonitrile and was evaporated to dryness under a nitrogen stream. The sample was reconstituted in 50 lL of water, of which 5 lL was injected into an Aqcuity ultra-performance liquid chromatography (UPLC) column (Waters, Waters Chromatography B.V., Etten-Leur, The Netherlands). The separation was achieved on a C18 reverse-phase analytical column (Acquity UPLC BEH C18 Column, 1.7 lm; 2.1 mm 9 100 mm) using a gradient elution with 50 mmol/L formic acid and 30 mmol/L ammonium acetate in water (mobile phase A) and 100% acetonitrile (mobile phase B) at a flow rate of 0.3 mL/min and a total run time of 11 min. The ultraviolet (UV) detector wavelength was set to 260 nm for TFV and 280 nm for FTC. The linearity of the calibration curve for TFV was over a concentration range of 25 ng/mL to 1200 lg/mL (R > 0.99), and for TFC was over a concentration range of 25-5000 ng/mL (R > 0.99).
Drug plasma concentrations collected post-dose were compared with previously published data obtained from formal pharmacokinetic studies in healthy volunteers assessing TFV and FTC plasma exposure, where the minimum value of the range at 24 h post-dose was established as the target: 19 ng/mL for TFV and 22 ng/mL for FTC [12] . Nonparametric Wilcoxon rank-sum testing was performed to compare the drug plasma concentrations between originator and generic TDF/FTC at the following time-points: 4, 12, and 24 h.
Renal function and HIV, HBV and HCV testing was also performed, at baseline and every 3-6 months. Subjects received risk reduction advice.
Renal function was evaluated from estimated glomerular filtration rates, creatinine levels, and urinalysis results for individuals with data available at both baseline and following PrEP initiation. Comparison of renal functions prior to and following the use of PrEP was performed using a nonparametric Wilcoxon signed-rank test for related samples.
Results
Data for 293 individuals taking generic PrEP purchased on the internet were collected. Baseline characteristics are shown in Table 1 and are compared to those in two large European PrEP clinical trials and to those of the "real world" population within the San Francisco Kaiser Permanente programme [1, 2, 12] , all of which enrolled men who have sex with men (MSM) at significant risk of HIV acquisition with high rates of sexually transmitted infections (STIs). All subjects were MSM, 85% were white, and their median (range) age was 38 (32-45) years; 56% said they were involved in "ChemSex" (sexual activity facilitated by the use of recreational drugs). Eightyfour per cent were taking PrEP daily, while the remaining 16% reported event-driven PrEP intake.
The online suppliers accessed by the PrEP users are summarized in Figure 1 . Ninety-two per cent purchased PrEP via www.iwantprepnow, a website set up by activists to support individuals wishing to obtain PrEP online by verifying the authenticity of online pharmacies and allowing individuals purchasing generic TDF/FTC to post testimonials on their website to share with other users of these generic products. This website enables users to click through to various online pharmacies to order PrEP supplies. Thirteen users (6%) accessed PrEP directly via www.alldaypharmacy.co.uk and four (2%) obtained it from other online sources.
The most common preparation purchased was Tenvir-EM (Cipla Pharmaceuticals, Mumbai, India), which was purchased by 98% of subjects; other preparations were Tavin-EM (Emcure Pharmaceuticals, Pune, India) and Ricovir-EM (Mylan N.V., Canonsburg, PA, USA) and Tencitab (Aspen Pharmaceutical, Durban, South Africa).
Blood samples for drug concentration measurement were drawn between 30 min and 27 h (median 15.5 h) after taking a PrEP pill.
The median (range) TFV and FTC concentrations were found to be 104 (21-597) ng/mL and 140 (17-1876) ng/mL, respectively. Plasma concentrations of TFV and FTC in this analysis either mirrored or were slightly higher than previously published data on plasma TFV and FTC concentrations in formal pharmacokinetic trials in HIV-negative healthy volunteers (Fig. 2) [12] . In a comparison of TFV concentrations at 4, 12 and 24 h post dose, these were slightly higher in the TDM service results (P = 0.02, 0.001, and 0.02, respectively). FTC concentrations were similar to clinical trial data 4 and 12 h post-dose (P > 0.05) and higher 24 h post-dose (P = 0.04).
TDM was repeated in 12 individuals only, where there was inadequate information on the timing of the last PrEP dose or sampling time, or when individuals reported changing supplier and re-attended the clinic. The concentrations of TFV and FTC were adequate for all repeated samples.
With regard to renal function, assay results were available in 145 individuals before PrEP initiation and at a follow-up visit (3-6 months) and were found to be within the normal range (P > 0.05).
Follow-up data were available in 201 individuals with a median of 91 follow-up days per person. No new HIV, HBV or HCV infections were diagnosed during this time.
Discussion
We report for the first time an evaluation of the outcomes of HIV-negative individuals purchasing generic TDF/FTC online. Importantly, we have seen no evidence of fake preparations. Table 1 Baseline characteristics of men who have sex with men (MSM) who underwent plasma tenofovir and emitricitabine preexposure prophylaxis (PrEP) therapeutic drug monitoring and comparison with the PROUD study [1] , the IPERGAY study [3] and the San Francisco Kaiser Permanente (SF KP) pre-exposure prophylaxis (PrEP) cohort study [14] This report is an example of a successful collaboration between patients, activists, clinicians and an academic laboratory, where TDM results were shared with patients, enabling them to inform others about their experiences and to identify safe sources of online PrEP.
Although this was not a clinical trial with the aim of assessing the efficacy of PrEP or optimal drug exposure, we can conclude that all individuals had plasma concentrations above our established TFV and FTC targets, based on previously published phase I formal pharmacokinetic clinical trials [12] . The use of a drug target derived from a previous publication only may be considered a limitation of this analysis, but minimum effective concentrations for plasma TFV and FTC do not exist either in the context of HIV treatment or in association with PrEP use.
If PrEP is unavailable on the NHS, it is nevertheless crucial that it is accessible to those at risk of infection [13] . Branded TDF/FTC formulations are unaffordable to most people and even generic preparations of TDF/FTC, despite being much cheaper than branded Truvada TM (Gilead, Foster City, CA, USA), remain inaccessible to many. People may be unaware that is legal to import generic medicines into the UK. Importantly, there are personal importation schemes in place to treat hepatitis C in several countries where cost restricts treatment for all, with encouraging results [14] .
Tools to limit the rapid growth of the HIV epidemic (the number of new diagnoses among MSM in the UK in 2014 was 3360, the largest number ever recorded, and remained high in 2015, with 3320 infections [15] ) are urgently warranted and PrEP significantly reduces the risk of HIV acquisition [1] [2] [3] .
As patents for antiretrovirals expire and generic versions of drugs such as TDF, FTC and lamiviudine (3TC) are imported, these drugs should become more affordable and enable large numbers of people in settings with limited health budgets to receive PrEP. 2 Plasma concentrations of (a) tenofovir (TFV) and (b) emtricitabine (FTC) measured in the 293 individuals who purchased preexposure prophylaxis (PrEP) on the internet (diamonds) and were offered therapeutic drug monitoring. These were compared to plasma concentrations of individuals using originator TFV disoproxil fumarate (TDF)/FTC (crosses), from previous research. The continuous line represents a fractional polynomial prediction plot fitted to drug plasma concentrations for individuals using originator TDF/FTC (Truvada TM ) [12] . Nevertheless, generic nucleoside reverse transcriptase inhibitors should become available in most countries by the end of 2016. Although the generic combination TDF/ FTC will not be available until 2021, TDF and 3TC may be available as two separate tablets initially, then combined in one tablet. It should be noted, however, that, although it is likely that 3TC will be as effective as FTC, there are currently no data to support this.
In conclusion, our evaluation showed that there are no concerns about generic TDF/FTC purchased on the internet from the sources we identified to be commonly used. However, we should not assume that all generic medicines purchased on the internet show therapeutic concentrations. It is therefore important to evaluate individual suppliers to ensure that medicines originate from an approved manufacturer.
An Australian prevention programme is currently importing generic TDF/FTC with the support of the government, and from next year TDF should be available in generic form in Europe and, we hope, will give many more people access to PrEP, if combination with 3TC is accepted.
Moreover, this will be a benchmark example for all medical specialties in case important treatment generic formulations become available to be purchased on the internet via uncontrolled means.
